Skip to main content
TipRanks
Go Ultimate75% OFF

Lyra Therapeutics (LYRA) Ratios

360 Followers

Lyra Therapeutics Ratios

LYRA's free cash flow for Q4 2025 was $-6.16M. For the 2025 fiscal year, LYRA's free cash flow was decreased by $-96.00K and operating cash flow was $-6.07M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio1.713.415.356.972.63
Quick Ratio1.713.415.356.972.63
Cash Ratio1.673.211.142.252.51
Solvency Ratio-0.61-1.70-1.17-1.86-2.07
Operating Cash Flow Ratio-3.03-5.54-3.23-3.00-1.42
Short-Term Operating Cash Flow Coverage0.000.000.000.000.00
Net Current Asset Value$ -30.55M$ -11.73M$ 51.64M$ 71.61M$ 27.37M
Leverage Ratios
Debt-to-Assets Ratio0.840.520.190.040.03
Debt-to-Equity Ratio-2.822.970.300.050.04
Debt-to-Capital Ratio1.550.750.230.050.04
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio-3.375.721.591.361.60
Debt Service Coverage Ratio0.000.000.000.000.00
Interest Coverage Ratio0.000.000.000.000.00
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share1.950.530.540.140.11
Net Debt to EBITDA-0.490.10-0.070.531.04
Profitability Margins
Gross Profit Margin100.00%100.00%100.00%100.00%-10318.95%
EBIT Margin-7425.38%-3959.13%-4205.91%-4034.48%-15303.51%
EBITDA Margin-7310.05%-3928.42%-4188.06%-3956.20%-14952.28%
Operating Profit Margin-7794.47%-6280.83%-4308.09%-4131.03%-15303.51%
Pretax Profit Margin-7263.32%-6088.40%-4019.32%-4054.66%-15267.72%
Net Profit Margin-7266.08%-6090.94%-4023.11%-4055.61%-15267.72%
Continuous Operations Profit Margin-7266.08%-6090.94%-4023.11%-4055.61%-15267.72%
Net Income Per EBT100.04%100.04%100.09%100.02%100.00%
EBT Per EBIT93.19%96.94%93.30%98.15%99.77%
Return on Assets (ROA)-80.09%-140.83%-43.96%-50.27%-79.31%
Return on Equity (ROE)269.84%-805.89%-70.10%-68.45%-126.80%
Return on Capital Employed (ROCE)-116.69%-179.37%-54.57%-58.96%-119.10%
Return on Invested Capital (ROIC)-98.78%-166.59%-52.26%-56.87%-115.71%
Return on Tangible Assets-80.09%-140.83%-43.96%-50.27%-79.31%
Earnings Yield-60.44%-13.90%-0.48%-1.16%-1.54%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover0.000.000.000.009.50
Inventory Turnover0.000.000.000.000.00
Fixed Asset Turnover0.020.070.040.310.05
Asset Turnover0.010.020.010.010.01
Working Capital Turnover Ratio0.020.030.020.020.01
Cash Conversion Cycle0.000.000.000.00-38.41
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding0.000.000.000.000.00
Days of Payables Outstanding0.000.000.000.0038.41
Operating Cycle0.000.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-1.86-1.08-1.27-1.43-1.99
Free Cash Flow Per Share-1.87-1.11-1.29-1.44-2.25
Dividend Paid and CapEx Coverage Ratio-248.78-29.94-60.46-264.54-7.63
Capital Expenditure Coverage Ratio-248.78-29.94-60.46-264.54-7.63
Operating Cash Flow Coverage Ratio-0.95-2.04-2.35-10.39-17.77
Operating Cash Flow to Sales Ratio-72.51-45.64-40.63-31.83-90.60
Free Cash Flow Yield-60.56%-10.77%-0.49%-0.92%-1.03%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.17-7.22-207.94-85.88-65.06
Price-to-Sales (P/S) Ratio120.22438.058365.503482.769933.23
Price-to-Book (P/B) Ratio-4.4657.96145.7658.7882.50
Price-to-Free Cash Flow (P/FCF) Ratio-1.65-9.29-202.54-109.00-96.93
Price-to-Operating Cash Flow Ratio-1.66-9.60-205.89-109.42-109.64
Price-to-Earnings Growth (PEG) Ratio-0.00-0.536.681.89-2.22
Enterprise Value Multiple-2.14-11.05-199.82-87.51-65.39
Enterprise Value62.21M665.78M13.04B4.72B2.79B
EV to EBITDA-2.14-11.05-199.82-87.51-65.39
EV to Sales156.31434.018368.413461.949777.81
EV to Free Cash Flow-2.15-9.20-202.61-108.35-95.42
EV to Operating Cash Flow-2.16-9.51-205.96-108.76-107.93
Tangible Book Value Per Share-0.690.181.802.672.64
Shareholders’ Equity Per Share-0.690.181.802.672.64
Tax and Other Ratios
Effective Tax Rate-0.00-0.00-0.00-0.000.00
Revenue Per Share0.030.020.030.050.02
Net Income Per Share-1.86-1.43-1.26-1.83-3.35
Tax Burden1.001.001.001.001.00
Interest Burden0.981.540.961.011.00
Research & Development to Revenue46.2628.5330.8328.46104.19
SG&A to Revenue28.9912.0612.2312.8849.85
Stock-Based Compensation to Revenue5.874.383.784.009.72
Income Quality1.000.751.010.780.59

Currency in USD